Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Rep. Quigley Introduces Bill to Reauthorize the ACT for ALS Act Through 2031
This bill was recently introduced and is currently being reviewed by the House Committee on Energy and Commerce. It is in the early stages of the legislative process and is considered active. There are no upcoming votes scheduled at this time.
Legislative Progress
This bill is a bipartisan update to a popular existing law. Since both parties usually support ALS research, it has a strong chance of passing through Congress.
Key Points
Impact Analysis
Personal Impact
People living with ALS (amyotrophic lateral sclerosis) would benefit from continued federal support for research into new treatments and expanded access to experimental therapies. ALS affects roughly 30,000 Americans at any given time, and this bill keeps the primary federal program focused on ALS treatment development alive through 2031. The broadened clinical trial definitions and enrollment oversight could speed up the path to new drugs reaching patients.
“To amend the Accelerating Access to Critical Therapies for ALS Act to reauthorize the provisions of such Act through fiscal year 2031, and for other purposes.”
Milestones
Referred to the House Committee on Energy and Commerce.
Introduced in House
The bill was officially filed and given a number. It now enters the legislative queue.
Votes
No votes have been recorded for this legislation yet.
Related News
2 articlesCalvert introduces bipartisan bill to reauthorize federal ALS programs
U.S. Rep. Ken Calvert (R-CA) and Mike Quigley (D-IL) introduced H.R. 8205 to reauthorize the ACT for ALS Act through 2031. The bill would codify eligibility guidelines for Expanded Access Programs, require a new FDA five-year action plan, and mandate a GAO report on program implementation by 2030.
Congress Considers Renewal of Act for ALS to Address Early-Stage Research Challenges
Congressional deliberations regarding the renewal of the Act for ALS are focusing on overcoming the 'Valley of Death' in drug development. Proponents argue that reauthorization is essential to prioritize early-stage research and streamline the path from breakthroughs to market-ready therapies.
Source Information
Document Type
Congressional Bill
Official Title
Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Data Sources
Sponsor
Cosponsors
(29)Analysis generated by AI. Always verify with official sources.